Prostate And Other Male Cancers

PARP-Inhibiting Drug May Improve mCRPC Outcomes

In a phase 3 trial of men with metastatic castration-resistant prostate cancer and altered DNA repair genes, olaparib-treated patients had significantly longer radiographic progression-free survival compared with enzalutamide or abiraterone recipients.

Erleada Approved for Metastatic Castration-Sensitive Prostate Cancer

The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Erleada (apalutamide; Janssen) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). The approval was supported by data from the phase 3 TITAN study, involving 1052 patients with mCSPC. Patients were randomized 1:1 to receive either Erleada plus…